ginkgo bioworks holdings - DNA
DNA
Close Chg Chg %
6.36 0.29 4.56%
Open Market
6.65
+0.29 (4.56%)
Volume: 525.67K
Last Updated:
Nov 21, 2024, 1:45 PM EDT
Company Overview: ginkgo bioworks holdings - DNA
DNA Key Data
| Open $6.39 | Day Range 6.28 - 6.69 |
| 52 Week Range 5.27 - 75.20 | Market Cap $346.49M |
| Shares Outstanding 54.48M | Public Float 37.16M |
| Beta 1.10 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$12.90 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.19M |
DNA Performance
| 1 Week | -0.16% | ||
| 1 Month | -22.06% | ||
| 3 Months | -21.96% | ||
| 1 Year | -89.11% | ||
| 5 Years | N/A |
DNA Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About ginkgo bioworks holdings - DNA
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
DNA At a Glance
Ginkgo Bioworks Holdings, Inc.
27 Drydock Avenue
Boston, Massachusetts 02210
| Phone | 1-877-422-5362 | Revenue | 251.46M | |
| Industry | Medical/Nursing Services | Net Income | -892,869,000.00 | |
| Sector | Health Services | Employees | 1,218 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
DNA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.068 |
| Price to Book Ratio | 2.898 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.293 |
| Enterprise Value to Sales | 10.256 |
| Total Debt to Enterprise Value | 0.094 |
DNA Efficiency
| Revenue/Employee | 206,449.097 |
| Income Per Employee | -733,061.576 |
| Receivables Turnover | 7.923 |
| Total Asset Turnover | 0.12 |
DNA Liquidity
| Current Ratio | 6.113 |
| Quick Ratio | 6.113 |
| Cash Ratio | 5.791 |
DNA Profitability
| Gross Margin | 56.727 |
| Operating Margin | -267.337 |
| Pretax Margin | -355.109 |
| Net Margin | -355.081 |
| Return on Assets | -42.47 |
| Return on Equity | -63.024 |
| Return on Total Capital | -66.686 |
| Return on Invested Capital | -51.484 |
DNA Capital Structure
| Total Debt to Total Equity | 22.036 |
| Total Debt to Total Capital | 18.057 |
| Total Debt to Total Assets | 14.518 |
| Long-Term Debt to Equity | 20.219 |
| Long-Term Debt to Total Capital | 16.568 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Ginkgo Bioworks Holdings - DNA
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 313.84M | 477.71M | 251.46M | |
Sales Growth
| - | - | +52.21% | -47.36% | - |
Cost of Goods Sold (COGS) incl D&A
| - | 144.59M | 265.85M | 108.81M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| - | 29.08M | 61.63M | 71.55M | |
Depreciation
| - | 27.88M | 56.03M | 55.85M | |
Amortization of Intangibles
| - | 1.20M | 5.60M | 15.70M | |
COGS Growth
| - | - | +83.86% | -59.07% | - |
Gross Income
| - | 169.25M | 211.86M | 142.64M | |
Gross Income Growth
| - | - | +25.18% | -32.67% | - |
Gross Profit Margin
| - | +53.93% | +44.35% | +56.73% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 5.00K | 2.00B | 2.37B | 814.87M | |
Research & Development
| - | 1.13B | 1.05B | 525.81M | |
Other SG&A
| 5.00K | 862.35M | 1.32B | 289.06M | |
SGA Growth
| - | +39,942,180.00% | +18.86% | -65.67% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | (79.34M) | (77.94M) | 187.01M | |
EBIT after Unusual Expense
| (5.00K) | (1.75B) | (2.08B) | (859.24M) | |
Non Operating Income/Expense
| - | (87.22M) | (37.31M) | (33.61M) | |
Non-Operating Interest Income
| - | 837.00K | 20.26M | 57.22M | |
Equity in Earnings of Affiliates
| - | (77.28M) | (43.76M) | (2.63M) | |
Interest Expense
| - | 2.37M | 106.00K | 93.00K | |
Interest Expense Growth
| - | - | -95.53% | -12.26% | - |
Gross Interest Expense
| - | 2.37M | 106.00K | 93.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (5.00K) | (1.84B) | (2.12B) | (892.94M) | |
Pretax Income Growth
| - | -36,762,340.00% | -15.41% | +57.91% | |
Pretax Margin
| - | -585.69% | -444.08% | -355.11% | |
Income Tax
| - | (1.48M) | (15.03M) | (71.00K) | |
Income Tax - Current - Domestic
| - | 1.00K | 271.00K | 690.00K | |
Income Tax - Current - Foreign
| - | - | 159.00K | 123.00K | - |
Income Tax - Deferred - Domestic
| - | - | (1.32M) | (14.44M) | - |
Income Tax - Deferred - Foreign
| - | (156.00K) | (1.01M) | (884.00K) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | (77.28M) | (43.76M) | (2.63M) | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (5.00K) | (1.84B) | (2.11B) | (892.87M) | |
Minority Interest Expense
| - | - | (6.59M) | (1.44M) | - |
Net Income
| (5.00K) | (1.83B) | (2.10B) | (892.87M) | |
Net Income Growth
| - | -36,600,840.00% | -15.02% | +57.58% | |
Net Margin Growth
| - | -583.12% | -440.63% | -355.08% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (5.00K) | (1.83B) | (2.10B) | (892.87M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (5.00K) | (1.83B) | (2.10B) | (892.87M) | |
EPS (Basic)
| -0.0008 | -45.4276 | -50.1452 | -18.368 | |
EPS (Basic) Growth
| - | -5,678,350.00% | -10.38% | +63.37% | |
Basic Shares Outstanding
| 5.39M | 40.28M | 41.98M | 48.61M | |
EPS (Diluted)
| -0.0008 | -46.8828 | -50.1452 | -18.368 | |
EPS (Diluted) Growth
| - | -5,860,250.00% | -6.96% | +63.37% | |
Diluted Shares Outstanding
| 5.39M | 40.28M | 41.98M | 48.61M | |
EBITDA
| (5.00K) | (1.80B) | (2.10B) | (600.68M) | |
EBITDA Growth
| - | -35,975,720.00% | -16.76% | +71.40% | |
EBITDA Margin
| - | -573.16% | -439.66% | -238.88% |
Snapshot
| Average Recommendation | UNDERWEIGHT | Average Target Price | 8.80 | |
| Number of Ratings | 6 | Current Quarters Estimate | -1.504 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -10.08 | |
| Last Quarter’s Earnings | -1.08 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -18.40 | Next Fiscal Year Estimate | -5.876 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 3 | 3 | 5 |
| Mean Estimate | -1.50 | -1.54 | -10.08 | -5.88 |
| High Estimates | -1.30 | -1.23 | -9.92 | -4.32 |
| Low Estimate | -1.74 | -1.89 | -10.30 | -7.84 |
| Coefficient of Variance | -11.01 | -21.55 | -1.95 | -25.62 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 3 | 3 | 3 |
| MEAN | Underweight | Underweight | Underweight |
SEC Filings for Ginkgo Bioworks Holdings - DNA
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Ginkgo Bioworks Holdings - DNA
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 6, 2024 | Steven P. Coen See remarks | 178,832 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.55 per share | 98,357.60 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 990,848 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 1,008,973 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 1,031,890 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 1,033,528 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 984,662 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.55 per share | 541,564.10 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 581,538 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 598,125 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Mark Dmytruk See remarks | 1,031,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Steven P. Coen See remarks | 192,272 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Steven P. Coen See remarks | 822,369 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Steven P. Coen See remarks | 186,023 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 6, 2024 | Steven P. Coen See remarks | 281,251 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2024 | Novalis Lifesciences LLC Director | 5,515,364 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.83 per share | 4,577,752.12 |
| May 17, 2024 | Shyam Sankar Director | 2,356,874 | Open market or private purchase of non-derivative security Non-derivative transaction at $0.82 per share | 1,932,636.68 |
| May 15, 2024 | Harry Evans Sloan Director | 718,540 | Open market or private purchase of non-derivative security Non-derivative transaction at $0.91 per share | 653,871.40 |
| May 15, 2024 | Marijn E. Dekkers Director | 281,217 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.93 per share | 261,531.81 |
| Apr 30, 2024 | Bartholomew Canton | 5,000,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 30, 2024 | Reshma Shetty | 5,000,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 30, 2024 | Reshma Shetty See remarks; Director | 5,000,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |